Nanobiotix S.A. - ADSs (NBTX)
Frequently Asked Questions About Nanobiotix S.A. - ADSs (NBTX)
Are there any regulatory approvals for Nanobiotix products?
As of now, Nanobiotix is in the clinical trial phase with its primary product, NBTXR3, which is not yet commercially approved. The company aims to achieve regulatory approvals from agencies like the FDA and EMA to bring their products to market once sufficient clinical data supports their safety and efficacy.
Has Nanobiotix published any results from its clinical trials?
Yes, Nanobiotix has published results from its clinical trials in peer-reviewed journals and presented findings at various scientific conferences. These results typically highlight the safety, efficacy, and novel mechanisms of action of NBTXR3, demonstrating its potential in cancer therapy.
How does Nanobiotix engage with investors?
Nanobiotix engages with investors through regular communications, including quarterly earnings reports, investor presentations, and participation in industry conferences. The company is committed to maintaining transparency and providing insights into its clinical progress and corporate strategies.
How does NBTXR3 work?
NBTXR3 works by accumulating in the tumor site and enhancing the effects of ionizing radiation. The nanoparticles are activated by radiation, leading to a dose amplification that increases the radiation dose delivered to the tumor cells while protecting surrounding healthy tissue, thus aiming to improve tumor response.
How does the company view the role of nanomedicine in cancer treatment?
Nanobiotix believes that nanomedicine holds great promise in revolutionizing cancer treatment by offering targeted and efficient therapeutic options. By utilizing the unique properties of nanoparticles, the company aims to enhance existing treatment modalities and improve patient outcomes in oncology.
How is Nanobiotix funded?
Nanobiotix has funded its operations through a combination of public offerings, private investments, and strategic partnerships. The capital raised is primarily used to support its clinical trials, research initiatives, and overall business development efforts.
Is Nanobiotix publicly traded?
Yes, Nanobiotix S.A. is publicly traded on the Nasdaq stock exchange under the ticker symbol NBTX. The company went public to raise capital for its clinical development programs while providing investors with an opportunity to participate in its growth and advancements in cancer treatment.
What are the clinical trials currently being conducted by Nanobiotix?
Nanobiotix is conducting several clinical trials to evaluate the safety and efficacy of NBTXR3 and its combination with radiotherapy in various cancer types. The trials aim to gather critical data that will support regulatory submissions and potentially lead to product approvals.
What challenges does Nanobiotix face in its operations?
Nanobiotix faces several challenges in its operations, including the complexities of clinical trial design, securing regulatory approvals, and navigating competitive pressures in the biotechnology sector. The company must also ensure adequate funding to support its research and operational needs as it advances its product pipeline.
What does Nanobiotix S.A. do?
Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing innovative nanomedicine therapies to improve cancer treatment. The company specializes in the design and development of proprietary nanomedicine products, including NBTXR3, which enhances the efficacy of radiotherapy by targeting tumor cells while minimizing damage to surrounding healthy tissue.
What is NBTXR3?
NBTXR3 is Nanobiotix's lead product candidate, designed to enhance the effectiveness of radiotherapy. It is an inorganic nanoparticle that, when injected directly into a tumor, increases the tumor's sensitivity to radiation, allowing for improved tumor control and potential therapeutic outcomes.
What is the company's approach to research and development?
Nanobiotix employs a rigorous research and development approach, combining cutting-edge nanotechnology with oncology expertise. The company collaborates with academic institutions, clinical researchers, and industry partners to ensure that its products are developed in line with the latest scientific advancements and patient needs.
What is the company's vision for the future?
Nanobiotix envisions transforming cancer treatment through its innovative nanomedicine products, aiming to improve patient outcomes and quality of life. The company seeks to establish itself as a leader in the biopharmaceutical sector by advancing its clinical programs and bringing new therapies to market.
What is the competitive landscape for Nanobiotix?
The competitive landscape for Nanobiotix includes various biotechnology and pharmaceutical companies developing innovative cancer therapies, including traditional chemotherapy, targeted therapies, and new entrants in the nanomedicine space. Nanobiotix differentiates itself through its unique approach to enhancing radiotherapy with nanotechnology.
What partnerships does Nanobiotix have?
Nanobiotix has established various partnerships with academic institutions, biopharmaceutical companies, and research organizations to enhance its development capabilities and expand its clinical research. These collaborations aim to leverage shared expertise and resources in the oncology field.
What types of cancer is Nanobiotix targeting?
Nanobiotix is focusing on a variety of cancer types, including but not limited to soft tissue sarcoma, head and neck cancer, and prostate cancer. The versatility of its nanomedicine approach allows it to explore therapeutic options across multiple malignancies.
When was Nanobiotix founded?
Nanobiotix was founded in 2003 by a team of experienced scientists and entrepreneurs. Since its inception, the company has focused on pioneering nanotechnology applications for cancer treatment, setting the stage for its innovative therapeutic solutions in oncology.
Where is Nanobiotix headquartered?
Nanobiotix is headquartered in Paris, France. This location provides the company with access to a vibrant biotech ecosystem and R&D infrastructure, enabling close collaboration with leading research institutions and healthcare professionals.
Who are the key members of Nanobiotix's management team?
The management team at Nanobiotix consists of experienced industry professionals with backgrounds in drug development, commercialization, finance, and regulatory affairs. Key figures include the CEO and other executives who guide the company in its strategic direction and operational execution.
What is the current price of Nanobiotix S.A. - ADSs?
The current price of Nanobiotix S.A. - ADSs is 3.380
When was Nanobiotix S.A. - ADSs last traded?
The last trade of Nanobiotix S.A. - ADSs was at 3:54 pm EDT on April 3rd, 2025
What is the market capitalization of Nanobiotix S.A. - ADSs?
The market capitalization of Nanobiotix S.A. - ADSs is 116.38M
How many shares of Nanobiotix S.A. - ADSs are outstanding?
Nanobiotix S.A. - ADSs has 34.43M shares outstanding.